Welcome to our dedicated page for PepGen SEC filings (Ticker: PEPG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The PepGen Inc. (PEPG) SEC filings page on Stock Titan provides access to the company’s official disclosures as filed with the U.S. Securities and Exchange Commission. As a Nasdaq Global Select Market issuer, PepGen uses current reports on Form 8-K, registration statements, and other filings to report material events related to its clinical-stage biotechnology business.
Through these filings, investors can review Form 8-K reports covering topics such as financial results for recent quarters, material financing transactions, executive appointments, equity compensation changes, and investor communications. For example, PepGen has filed 8-Ks announcing quarterly financial results, the launch and pricing of an underwritten public offering under a shelf registration statement on Form S-3, and the appointment of a Chief Business and Legal Officer. Other 8-Ks describe an option repricing for employee stock options under the company’s 2020, 2022, and 2024 equity plans, and the furnishing of updated corporate presentations and clinical data summaries.
Filings also confirm that PepGen’s common stock, par value $0.0001 per share, is registered under Section 12(b) of the Exchange Act and trades on the Nasdaq Global Select Market under the symbol PEPG. Registration statements and prospectus supplements referenced in the filings outline how the company issues shares to fund its Enhanced Delivery Oligonucleotide (EDO) platform and clinical programs, including the FREEDOM-DM1 and FREEDOM2-DM1 trials of PGN-EDODM1 in myotonic dystrophy type 1.
On Stock Titan, these SEC documents are paired with AI-powered summaries that highlight key points from lengthy filings, helping users quickly identify items such as new financings, changes in executive leadership, or updates to clinical and investor presentations. Real-time updates from EDGAR, combined with AI explanations of complex legal and financial language, allow investors to follow PepGen’s regulatory history, capital-raising activities, and material corporate events without reading every line of each filing.
PepGen Inc. furnished an updated corporate presentation as of October 1, 2025. The company submitted the revised presentation as Exhibit 99.1 under a Regulation FD disclosure, meaning it is being provided for informational purposes and is not treated as filed financial reporting. The presentation is incorporated by reference only if specifically cited in future documents and the company notes that its inclusion does not, by itself, indicate that the information is material.
Oxford Science Enterprises plc reports beneficial ownership of 4,955,388 shares of PepGen Inc. common stock, representing 7.21% of the outstanding shares based on the issuer's stated total of 68,737,224 shares. The reporting person discloses sole voting and sole dispositive power over these shares and indicates the holdings were not acquired to influence control of the issuer.
The statement references the issuer's prospectus supplement for the share count used to calculate the percentage and otherwise confirms no group affiliations, no shared voting or dispositive powers, and that the position is held directly by Oxford Science Enterprises plc.
Oxford Science Enterprises plc reported purchasing 200,000 shares of PepGen Inc. common stock on September 30, 2025 at $3.20 per share in the issuer's public offering. After the purchase, Oxford Science Enterprises beneficially owned 4,955,388 shares. The issuer disclosed there were 68,737,224 shares outstanding as of September 26, 2025, which means Oxford Science Enterprises no longer beneficially owns more than 10% of PepGen's common stock. As a result, Oxford Science Enterprises is no longer subject to Section 16 reporting obligations for PepGen common stock and indicated it will not file further Form 4 or Form 5 reports for these holdings.
PepGen Inc. (PEPG) is the subject of Amendment No. 4 to a Schedule 13D filed by RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah and RA Capital Healthcare Fund, L.P. Collectively the Reporting Persons beneficially own 20,099,753 shares, equal to 29.2% of the outstanding common stock based on 68,737,224 shares outstanding. The Fund acquired 9,375,000 shares in PepGen's 2025 public offering at $3.20 per share for an aggregate purchase price of $30.0 million, funded from the Fund's working capital. Certain employee options totaling up to 11,667 shares vest on schedule and a customary 60-day lock-up from the offering applies to directors and officers.
PepGen, Inc. (PEPG) disclosed an underwritten offering and related materials intended to fund its clinical programs and general corporate needs. The company says proceeds are expected to support the FREEDOM-DM1 and FREEDOM2-DM1 clinical trials and for working capital and other general corporate purposes. The filing references an initial registration statement filed June 28, 2024 and declared effective July 8, 2024. The company expects the offering to close on or about September 26, 2025, subject to customary closing conditions. Listed exhibits include an Underwriting Agreement dated September 24, 2025, legal opinion and consent from Goodwin Procter LLP, launch and pricing press releases dated September 24, 2025, and an Inline XBRL cover page. The form is signed by CFO Noel Donnelly on September 26, 2025.
PepGen Inc. is offering common stock at $3.20 per share to raise up to $100,000,000 (approximately $115,000,000 if the underwriters exercise their 30-day option in full for an additional 4,687,500 shares). Underwriting discounts of $0.192 per share (about $6,000,000 without option, $6,900,000 with option) are disclosed. Net proceeds are earmarked primarily to fund the FREEDOM-DM1 and FREEDOM2-DM1 clinical trials, working capital and general corporate purposes, with management retaining broad discretion over final allocation. Lock-up agreements apply to certain holders and may be released early at the underwriters’ discretion. PepGen’s common stock trades on Nasdaq under PEPG. The company completed a November 23, 2020 reorganization that made PepGen Inc. the sole shareholder of PepGen Limited and adopted PepGen Limited’s historical financial statements. As of September 24, 2025, PepGen sold 1,000,000 shares under an at-the-market program for gross proceeds of $10 million.
PepGen Inc. is offering shares of common stock and pre-funded warrants as described in this prospectus supplement. Each pre-funded warrant is exercisable for one share at an exercise price of $0.0001, does not expire, and includes ownership limitations (default 4.99%, elective 9.99%, adjustable up to 19.99% after 61 days). The prospectus warns purchasers of immediate dilution and potential further dilution from future issuances or option exercises. Proceeds are stated to fund FREEDOM-DM1 and FREEDOM2-DM1 clinical trials, working capital and corporate purposes, though management retains broad discretion over allocation. The common stock trades on the Nasdaq Global Select Market under the symbol PEPG. The document discloses underwriting arrangements, lock-up provisions, and U.S. and non-U.S. tax considerations for holders.
PepGen Inc. furnished an update on its DM1 program through a press release and an investor presentation. The company reported in the press release that it achieved what it describes as the highest mean splicing correction ever reported in patients with myotonic dystrophy type 1 (DM1). In addition, PepGen filed an updated presentation titled “Freedom-DM1, 15 mg/gk Cohort Data Update,” which its representatives plan to use in meetings with investors. The press release is provided as Exhibit 99.1 and the data update presentation as Exhibit 99.2.
PepGen Inc. schedules a passive ownership disclosure showing Suvretta Capital Management, Averill Master Fund and Aaron Cowen each report shared beneficial ownership of 300,000 shares of PepGen common stock, equal to 0.9% of the class. The filing states the reporting persons have shared voting and shared dispositive power over those shares, and that the securities are directly owned by advisory clients of Suvretta Capital Management. The report also states no reported holder is known to beneficially own more than 5% of the common stock and includes a disclaimer that reported persons disclaim beneficial ownership except for pecuniary interest. The filing affirms the securities were not acquired to influence control.